Cargando…

Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy

Ovarian cancer is the leading cause of death from gynaecological malignancy. Despite improved detection and treatment options, relapse rates remain high. Combining immunotherapy with the current standard treatments may provide an improved prognosis, however, little is known about how standard chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Anthony, Govindaraj, Chindu, Xiang, Sue D., Halo, Julene, Quinn, Michael, Scalzo-Inguanti, Karen, Plebanski, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712704/ https://www.ncbi.nlm.nih.gov/pubmed/24213326 http://dx.doi.org/10.3390/cancers4020581

Ejemplares similares

TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors
por: Govindaraj, Chindu, et al.
Publicado: (2013)

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations
por: Madondo, Mutsa T, et al.
Publicado: (2014)

Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope
por: Wilson, Kirsty L., et al.
Publicado: (2015)

Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities
por: Cassar, Emily, et al.
Publicado: (2022)

Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2020)

Type of chemotherapy has substantial effects on the immune system in ovarian cancer
por: Vankerckhoven, Ann, et al.
Publicado: (2021)

Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies
por: Cook, Alistair M., et al.
Publicado: (2015)

Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2017)

Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
por: Kang, Sung-Woog, et al.
Publicado: (2021)

The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
por: Koumarianou, Anna, et al.
Publicado: (2014)

Substantial Conformational Change Mediated by Charge-Triad Residues of the Death Effector Domain in Protein-Protein Interactions
por: Twomey, Edward C., et al.
Publicado: (2013)

Side Effects: Substantial Non-Neutral Evolution Flanking Regulatory Sites
por: Prendergast, James G. D., et al.
Publicado: (2013)

Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells
por: Holtappels, Rafaela, et al.
Publicado: (2023)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Anti-regulatory T cells are natural regulatory effector T cells
por: Ødum, Niels
Publicado: (2019)

Peripheral effector memory regulatory T cells are incremented and functionally enhanced in successful mite monomeric allergoid sublingual immunotherapy
por: Petrarca, Claudia, et al.
Publicado: (2020)

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(®) in combination with chemotherapy
por: Kumar, Chaitanya, et al.
Publicado: (2019)

Unusual association of transposition of great arteries with infradiaphragmatic pulmonary venous return
por: Scrascia, Giuseppe, et al.
Publicado: (2020)

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2015)

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
por: Hong, Megan M Y, et al.
Publicado: (2022)

A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines
por: Wilson, Kirsty L., et al.
Publicado: (2016)

Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues
por: Wilson, Kirsty L., et al.
Publicado: (2020)

Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
por: Rajasekaran, Kamalakannan, et al.
Publicado: (2016)

PKC-Theta in Regulatory and Effector T-cell Functions
por: Brezar, Vedran, et al.
Publicado: (2015)

Lineage Reprogramming of Effector Regulatory T Cells in Cancer
por: Dixon, Michael L., et al.
Publicado: (2021)

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
por: Thelen, Martin, et al.
Publicado: (2021)

Substantiating efficacy of probiotics
por: Mercenier, Annick
Publicado: (2011)

Substantial Annual Distribution
Publicado: (1920)

The Use of Synthetic Carriers in Malaria Vaccine Design
por: Powles, Liam, et al.
Publicado: (2015)

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
por: Gao, Qian, et al.
Publicado: (2018)

Regulatory T Cells as Immunotherapy
por: Singer, Benjamin D., et al.
Publicado: (2014)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
por: Lupo, Kyle B., et al.
Publicado: (2019)

The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
por: Lim, Aaron R, et al.
Publicado: (2020)

Transcriptional Regulation of Differentiation and Functions of Effector T Regulatory Cells
por: Koizumi, Shin-ichi, et al.
Publicado: (2019)

Effector and Regulatory T Cell Trafficking in Corneal Allograft Rejection
por: Amouzegar, Afsaneh, et al.
Publicado: (2017)

Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films
por: Proudfoot, Owen, et al.
Publicado: (2008)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

Interferon Regulatory Factor 4 controls T(H1) cell effector function and metabolism
por: Mahnke, Justus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1kh4v7ut3huirtt64tovu9khnq